The PAX8 cistrome in epithelial ovarian cancer by Adler, E et al.
Oncotarget108316www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 65), pp: 108316-108332
The PAX8 cistrome in epithelial ovarian cancer
Emily K. Adler1,*, Rosario I. Corona2,3,*, Janet M. Lee2, Norma Rodriguez-Malave2, 
Paulette Mhawech-Fauceglia4, Heidi Sowter5, Dennis J. Hazelett2,**, Kate 
Lawrenson2,3,** and Simon A. Gayther2,3,**
1 Department of Preventive Medicine, University of Southern California/Keck School of Medicine, Los Angeles, California, USA
2 Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical 
Center, Los Angeles, California, USA
3 Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, 
California, USA
4 Departments of Medicine and Pathology, University of Southern California/Keck School of Medicine, Los Angeles, California, 
USA
5 Department of Biomedical Science and Public Health, University of Derby, Derby, UK
* These authors have contributed equally to this study
** Jointly lead the study
Correspondence to: Kate Lawrenson, email: kate.lawrenson@cshs.org
Correspondence to: Simon A. Gayther, email: Simon.Gayther@cshs.org
Keywords: PAX8, transcription factor, ovarian cancer, chromatin immunoprecipitation, ChIP-seq
Received: August 24, 2017 Accepted: September 30, 2017 Published: November 27, 2017
Copyright: Adler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
PAX8 is a lineage-restricted transcription factor that is expressed in epithelial 
ovarian cancer (EOC) precursor tissues, and in the major EOC histotypes. Frequent 
overexpression of PAX8 in primary EOCs suggests this factor functions as an oncogene 
during tumorigenesis, however, the biological role of PAX8 in EOC development 
is poorly understood. We found that stable knockdown of PAX8 in EOC models 
significantly reduced cell proliferation and anchorage dependent growth in vitro, 
and attenuated tumorigenicity in vivo. Chromatin immunoprecipitation followed by 
next generation sequencing (ChIP-seq) and transcriptional profiling were used to 
create genome-wide maps of PAX8 binding and putative target genes. PAX8 binding 
sites were significantly enriched in promoter regions (p < 0.05) and superenhancers 
(p < 0.05). MEME-ChIP analysis revealed that PAX8 binding sites overlapping 
superenhancers or enhancers, but not promoters, were enriched for JUND/B and 
ARNT/AHR motifs. Integrating PAX8 ChIP-seq and gene expression data identified 
PAX8 target genes through their associations within shared topological association 
domains. Across two EOC models we identified 62 direct regulatory targets based on 
PAX8 binding in promoters and 1,330 putative enhancer regulatory targets. SEPW1, 
which is involved in oxidation-reduction, was identified as a PAX8 target gene in 
both cell line models. While the PAX8 cistrome exhibits a high degree of cell-type 
specificity, analyses of PAX8 target genes and putative cofactors identified common 
molecular targets and partners as candidate therapeutic targets for EOC.
INTRODUCTION
PAX8 encodes a member of the paired box family 
of transcription factors (TFs) that is essential for normal 
embryonic development of the Müllerian ducts [1]. The 
role of PAX8 in the functioning of the kidney and thyroid 
is established; but more recently this TF been recognized 
as a key driver in the development of epithelial ovarian 
cancer (EOC). PAX8 is overexpressed in about 80% of the 
most common EOC histotype, high-grade serous ovarian 
cancer (HGSOC) [2-5]. PAX8 expression is routinely 
used clinically as a molecular maker to identify tumors 
of Müllerian origin [6, 7]. Different EOC histotypes arise 
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from different cellular origins, many of which also express 
PAX8: normal fallopian tube secretory epithelial cells and 
ovarian surface epithelial cells, possible precursors of 
HGSOCs, and endometrial and endocervical epithelial 
cells, precursors of clear cell and endometrioid EOCs, all 
express PAX8 [7-9]. 
PAX8 may also be be involved in genetic 
susceptibility to ovarian cancer, possibly with subtype-
specific biological roles in EOC initiation. The genomic 
region containing PAX8 is a common low penetrance 
susceptibility locus for mucinous ovarian cancer [10], 
and we recently identified PAX8 as a master regulator 
associated with susceptibility to serous ovarian cancer 
[11], suggesting that PAX8 may be a regulator of early 
EOC development and that transcriptional programs 
induced by PAX8 overexpression promote malignant 
transformation. 
Although PAX8 is a common marker in HGSOC, 
the biological role of this gene is poorly understood in 
this subtype, and even less so in the other, less common 
histological subtypes. PAX8 knockdown in ovarian cancer 
cell lines reduces in vitro and in vivo tumorigenicity and 
induces apoptosis [12-15]. However, the functional role 
of PAX8 in EOC development is poorly understood. A 
detailed mechanistic understanding of the PAX8 cistrome 
will be key to any future development of agents targeting 
PAX8 as a therapy for EOC.
RESULTS
PAX8 expression in ovarian cancer histotypes
Analysis of The Cancer Genome Atlas (TCGA) data 
indicates that PAX8 mRNA expression is significantly 
upregulated in high-grade serous ovarian cancers 
(HGSOC) compared to normal fallopian tube tissues 
(p = 0.007) (Table 1); but the role of PAX8 in other 
ovarian cancer histotypes is poorly understood. We 
used immunohistochemistry to evaluate PAX8 protein 
expression in ~160 primary ovarian tumors representing 
the four major histotypes of EOC - HGSOC, clear 
cell ovarian cancer (CCOC), endometrioid ovarian 
cancer (EnOC) and mucinous ovarian cancer (MOC). 
Representative staining can be found in Figure 1a. PAX8 
was most highly expressed in HGSOCs (88%) and CCOCs 
(89%) (p = 0.007), but was also expressed in over half 
of MOCs and EnOCs suggesting that PAX8 is a pan-
EOC marker (Table 2). Highest PAX8 expression was 
associated with advanced stage carcinomas, compared to 
low stage carcinomas (p = 0.013), but did not correlate 
with tumor grade (Table 2).
We also performed semi-quantitative real-time RT-
PCR (RT-qPCR) in 72 primary ovarian cancer precursor 
cells (66 normal ovarian epithelial and 6 normal fallopian 
tube secretory epithelial cell cultures) and 58 ovarian 
cancer cell lines derived from a range of ovarian cancer 
histotypes. These data were consistent with the results 
of immunohistochemistry analyses: PAX8 was expressed 
at higher levels in EOC cell lines compared to normal 
precursor cells (p < 0.0001, two-tailed unpaired T-test). 
Highest PAX8 expression was observed in HGSOC 
and CCOC cell lines (Figure 1). There was significant 
variation in PAX8 expression across EOC histotypes (p < 
0.0002, one-way ANOVA), with PAX8 overexpressed in 
serous ovarian cancer (n=16), CCOC (n=18) and MOC 
cell lines (n=2), but not in EnOC lines (n=3) lines. Taken 
together, these data suggest that PAX8 may function as 
an oncogene in the development of most EOC histotypes. 
Figure 1: PAX8 gene expression in EOC subtypes and precursor cells. a. Representative immunohistochemical staining for 
PAX8 in tumor specimens. b. PAX8 gene expression measured by qPCR. OSEC, ovarian surface epithelial cells; FTSEC, fallopian tube 
secretory epithelial cells; SOC, serous ovarian cancer; CCOC, clear cell ovarian cancer; EnOC, endometrioid ovarian cancer; MOC, 
mucinous ovarian cancer; EOC, epithelial ovarian cancer. Samples were relative to OSEC250, which has an average level of PAX8 
expression among OSECs, * p < 0.05 compared to OSECs and FTSECs, two-tailed unpaired T-test.
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PAX8 knockdown reduces anchorage dependent 
and independent growth 
PAX8 was stably knocked down using two 
independent shRNAs, in the HeyA8 and IGROV1 EOC 
cell lines. Both lines represent models of high-grade 
ovarian adenocarcinoma but no specific histological 
subtype. A control line expressing a non-silencing 
‘scrambled’ shRNA hairpin (shScr) was also generated 
for each line. In HeyA8 we achieved a 74% and 58% 
reduction in PAX8 expression for shPAX8_1 and 
shPAX8_2 transduced lines respectively (p > 0.05) (Figure 
2a). In IGROV1 we achieved 70% and 79% reduction 
in PAX8 expression for shPAX8_3 and shPAX8_4, 
respectively (p > 0.05) (Figure 2b). In both cell lines we 
observed negligible changes in PAX8 expression in shScr 
controls compared to parental cells. Immunofluorescent 
Table 1: PAX gene expression in normal fallopian tubes and high-grade serous ovarian cancers from The Cancer 
Genome Atlas.
Gene Name P-value Mean Expression in HGSOC (n=489)
Mean Expression in 
Normal FT (n=8)
Mean Difference 
HGSOC v FT
PAX8 0.007 0.044 -0.496 0.540
PAX6 1.22E-09 0.033 -0.435 0.468
PAX7 0.309 -0.016 0.018 -0.035
PAX4 0.056 -0.005 0.098 -0.103
PAX1 3.26E-05 -0.009 0.111 -0.120
PAX9 0.148 0.006 0.129 -0.123
PAX3 0.015 -0.020 0.193 -0.213
PAX5 0.041 -0.010 0.222 -0.231
PAX2 3.80E-06 -0.028 1.157 -1.184
Ranked in order of mean change in expression in tumors compared to normal tissues.
Table 2: PAX8 expression in EOC histotypes. 
PAX8 staining
N (%) P-value†Clinical Feature Low/Absent Medium/High
Stage
1 17 (30) 39 (70) 0.013*
2 6 (21) 22 (79)
3 16 (14)* 101 (86)*
4 5 (20) 20 (80)
Grade
G1 2 (7) 25 (93) 0.072
G2 11 (24) 35 (76)
G3 30 (20) 121 (80)
Residual Disease
Optimal debulking 21 (22) 73 (78) 0.391
Sub-optimal debulking 22 (17) 106 (83)
Histological type
Serous 15 (12)* 109 (88)* 0.007*
Mucinous 6 (35) 11 (65)
Endometrioid 9 (29) 22 (71)
Clear Cell 2 (11)* 16 (89)*
Undifferentiated 10 (29) 24 (71)
Borderline 3 (43) 4 (57)
A significantly higher number of stage 3 and serous and clear cell ovarian carcinomas express high/medium 
levels of PAX8 (denoted by *). †The Pearson Chi Squared test was used to derive the p-values.
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staining confirmed a marked reduction in PAX8 protein 
expression in shPAX8 transduced cell lines compared to 
shScr and parental controls (Figure 2c & 2d). 
PAX8 knockdown was associated with a significant 
reduction in anchorage-independent growth compared to 
shScr (HeyA8 shPAX8_1, p = 0.003; HeyA8 shPAX8_2, 
p = 0.003; IGROV1 shPAX8_3, p = 0.0008; IGROV1 
shPAX8_4, p = 0.0007) (Figure 2e & 2f). We also 
observed significant increases in population doubling 
times in all PAX8 knockdown models compared to 
shScr cell lines (HeyA8 shPAX8_1, p = 0.004; HeyA8 
shPAX8_2 p = 0.004; IGROV1 shPAX8_3, p = 0.008; 
IGROV1 shPAX8_4, p = 0.011) (Figure 2g & 2h).
PAX8 knockdown impairs tumorigenicity in vivo
We next examined the effects of PAX8 knockdown 
on in vivo tumorigenicity in HeyA8 models. For parental 
and shScr-expressing HeyA8 cells we observed abdominal 
distention four weeks after intraperitoneal injection of 
tumor cells, indicative of significant tumor burden (Figure 
3a & 3b). Detailed examination of the abdominal cavity 
during necropsy identified tumor spread throughout the 
peritoneal cavity in all 4 HeyA8 and in 4/5 HeyA8+shScr 
injected mice. Pathological examination of tumors formed 
in HeyA8 and HeyA8+shScr mice classified these tumors 
as high-grade poorly differentiated adenocarcinomas, 
consistent with the known pathology of the HeyA8 cancer 
cell line. In contrast, HeyA8+shPAX8-1 injected mice 
Table 3: Candidate PAX8 co-regulators. 
Motif/Factor
HeyA8 IGROV1
All Superenhancer Promoter Enhancer All
Super 
enhancer Promoter Enhancer
PAX5 -75.64 -122.14 -75.64 -237.09 -84.48 -156.36 -84.48 -276.91
PAX2 -76.06 -140.02 -76.06 -242.56 -90.26 -202.7 -90.26 -253.45
PAX1 -42.29 -85.93 -42.29 -121.7 -38.96 -114.76 -38.96 -138.49
PAX6 -38.46 -121.77 -38.46 -133.79 -16.11 -94.49 -16.11 -127.34
PAX9 -35.48 -58.45 -35.48 -83.5 -26.75 -76.52 -26.75 -95.52
TEAD3 0 0 0 0 0 -14.77 0 -25.26
Arnt::Ahr 0 -12.34 0 -16.12 0 -13.64 0 -23.05
TEAD1 0 0 0 0 0 -22.46 0 -11.55
Zbtb3_primary 0 0 0 -7.92 0 0 0 -14.5
GMEB2 0 0 0 -6.17 0 0 0 -14.07
Klf4 0 0 0 0 0 0 0 -11.27
Zfp161_secondary 0 0 0 0 0 0 0 -9.9
JUND 0 -5.81 0 -5.13 0 -8.61 0 0
SP1 0 0 0 0 0 0 0 -8.61
Sp4_secondary 0 0 0 0 0 0 0 -8.25
FOS 0 -5.52 0 -5.23 0 0 0 -8.21
JUNB 0 -5.02 0 -5.18 0 -8.2 0 0
HIF1A::ARNT 0 0 0 0 0 -7.76 0 -6.05
Klf1 0 0 0 0 0 0 0 -7.47
KLF5 0 0 0 0 0 0 0 -6.28
Nfe2l2 0 0 0 -6.2 0 0 0 0
Max_secondary 0 0 0 0 0 0 0 -5.71
NFIA 0 0 0 0 0 0 0 -5.43
Klf7_primary 0 0 0 0 0 0 0 -5.19
KLF14 0 0 0 0 0 0 0 -5.12
NFYA 0 0 0 0 0 0 0 -5.07
Log adjusted p-values of motifs found within 50 bases of PAX8 binding site summits of HeyA8 and IGROV1 using all, 
superenhancer, promoter and enhancer-associated PAX8 binding sites.
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demonstrated modest tumor growth, with smaller tumors 
compared to controls. There was no evidence of tumor 
growth in HeyA8+shPAX8_2 mice (n=3) (Figure 3c). 
Subsequent pathological analyses of HeyA8+shPAX8_2 
mice confirmed the absence of tumor deposits in peritoneal 
tissues harvested from these mice, which resembled the 
phenotype of mice injected with vehicle alone (n=3). 
Characterizing the PAX8 cistrome 
To characterize the PAX8 cistrome we performed 
chromatin immunoprecipitation followed by next 
generation sequencing (ChIP-seq) to catalogue PAX8 
binding sites in HeyA8 and IGROV1 cell lines. In parallel 
we performed ChIP-seq for acetylation of lysine 27 on 
histone subunit 3 (H3K27ac) to identify when PAX8 
binding coincided with active chromatin. 
We identified 2918 sites (average length 566 bp) 
throughout the genome where PAX8 binds in HeyA8 cells, 
and 3028 PAX8 binding sites (average length = 673 bp) 
in IGROV1 cells. PAX8 binding sites were significantly 
enriched in promoter regions in both cell lines (p < 0.05, 
Fisher’s exact test). Approximately 6% (n=182) and 16% 
(n=478) of all PAX8 binding sites fell in promoter regions 
in HeyA8 and IGROV1 cells, respectively (Figure 4a & 
4b). Although more than 60% of PAX8 binding sites were 
outside promoters or gene bodies, we did not find evidence 
for enrichment in intergenic regions, even when repeat-
rich regions were excluded. There were 653 PAX8 binding 
sites in common between the two cell lines (Figure 4c). 
There were some significant differences in the PAX8 
cistrome between the two cell lines: for example, 60% 
(n=1829) of PAX8 binding sites in IGROV1 overlapped 
with H3K27ac positive regions compared to only ~25% 
(n=731) of PAX8 binding sites in HeyA8 cells, even 
though we observed 2.5 times more H3K27ac positive 
regions in HeyA8 cells. 
We catalogued superenhancers in the two cell lines, 
defined as enhancers >10kb that are highly enriched in 
H3K27ac and lineage-specific transcription factors [16]. 
Based on the H3K27ac ChIP-seq data we characterized 
391 superenhancers (average length = 126K bp) in HeyA8 
and 523 superenhancers (average length = 71K bp) in 
Figure 2: In vitro analysis of PAX8 knockdown models. PAX8 was stably knocked down using short hairpin RNAs (shRNAs). 
PAX8 gene expression in knockdown and control lines in a. HeyA8 and b. IGROV1 ovarian cancer cell lines. Knockdown of PAX8 
protein was confirmed by immunofluorescent staining in c. HeyA8 and d. IGROV1 cells. Nuclei were counterstained with Hoescht DNA 
stain. 200X magnification is shown. e.-f. Anchorage independent growth assays in (e) HeyA8 and (f) IGROV1 PAX8 knockdown models. 
(g-h) Anchorage dependent growth assays in g. HeyA8 and h. IGROV1 models. Data shown are mean ± standard deviation, and are 
representative of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed paired T-test. In panels (g) and 
(h) T-tests values (two tailed, paired) for knockdown lines compared to shScr lines are indicated. 
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IGROV1. HeyA8 PAX8-binding sites were significantly 
enriched at superenhancers; there were approximately 326 
(11%) PAX8 binding sites in superenhancer regions (odds 
ratio 1.82; p < 0.01).
Characterizing the PAX8 binding motif 
We used MEME-ChIP suite to characterize a PAX8 
binding motif from the PAX8 ChIP-seq data from each 
cell line. For HeyA8, we included 2,923 sequences 
centered in the summit of the PAX8 binding sites. The 
motif shown in Figure 5a for HeyA8 was present in 2,127 
(73%) of all the sequences, and centered, on average, 4.5 
bp off the center of the sequences. For IGROV1, we used 
3,029 total input sequences centered in the summit of the 
IGROV1 PAX8 binding sites, from which 1,415 (47%) 
have the motif shown in Figure 5a for IGROV1, and the 
motif is centered, in average, 1.5 bp off the center of the 
input sequences. Crucially, we identified the same PAX-
like motif in both cell lines. This motif correlates with 
a PAX8-dsDNA homology model we generated using 
the PAX5-dsDNA complex (PDB id: 1k78, sequence 
identity = 85%) as a template. The homology model has 
high structure similarity to this template (RMSD = 0.2) 
and to another PAX8 homolog, PAX6-dsDNA (PDB id: 
6pax; sequence identity = 72%; RMSD = 1.6). The protein 
side-chain/DNA-base contacts observed in the homology 
model extend 17 base pairs. First, the PAI subdomain 
makes contact with 5 continuous bases in the major 
groove and one base in the minor groove, followed by 
the linker that makes contact with 3 non-continuous bases 
in the minor groove. At the C terminus of the PAIRED 
DNA binding domain, the RED subdomain makes contact 
with 4 continuous bases via the major groove. Since it 
is known that protein side-chain/DNA-major groove 
contacts provide higher specificity than contacts in the 
minor groove, the expected motif would have a region 
of medium to low specificity (provided by the linker) in 
the middle, flanked by a couple of highly-specific bases 
(provided by the PAI and RED subdomains), exactly the 
pattern exhibited in the PAX-like motif we identified 
(Figure 5a).
Figure 3: In vivo analysis of PAX8 knockdown models. a. In vivo growth of HeyA8 PAX8 models, representative images of 
peritoneal cavities. Tumors are indicated with an asterisk. b. Reproductive tracts in xenograft models, tumors are indicated with arrowheads. 
O, ovary; T, oviduct (murine fallopian tube); U, uterine horn; shScr, non-targeting control shRNA. c. Quantitative analysis of largest tumor 
volume. * p < 0.05 versus parental cells. Two tailed unpaired T-test.
Figure 4: PAX8 ChIP-seq binding sites for HeyA8 and IGROV1. a. Distribution of PAX8 binding sites across promoter, gene 
body, superenhancer, and enhancer regions of the human genome for PAX8 binding sites in HeyA8 (orange), IGROV1 (blue), and the 
intersection of the two sets (yellow). Distribution of the distance of the PAX8 binding sites in HeyA8 (orange) and IGROV1 (blue) with 
regards to the closest transcription start site (TSS) normalized by the number of PAX8 binding sites in HeyA8 and IGROV1, respectively. 
Venn diagrams showing the number of (c) PAX8 binding sites in HeyA8 (orange) and IGROV1 (blue).
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Identifying PAX8 candidate co-regulators 
To identify candidate co-regulators, that may 
cooperate with PAX8 to regulate gene expression, we 
divided all PAX8 peaks that overlap H3K27ac into three 
non-overlapping sets: (1) PAX8 binding sites that overlap 
superenhancer regions, (2) PAX8 binding sites that overlap 
promoter regions defined as 1000 bp upstream and 100 bp 
downstream of the transcription start site of a gene, and (3) 
PAX8 binding sites that neither overlap superenhancers, 
nor promoters, but overlap H3K27ac marks (i.e. typical 
enhancers). PAX motifs were significantly enriched in all 
classes of PAX8 binding sites in both cell lines (Figure 
5b, Table 3). In both cell lines we found enrichment of 
Arnt::Ahr motifs for PAX8 binding sites overlapping 
superenhancers or enhancers, but not promoters (in 
HeyA8 superenhancers, p = 4.37x10-6; in HeyA8 typical 
enhancers, p = 9.98x10-8; in IGROV1 superenhancers, p 
= 1.19x10-6; in IGROV1 typical enhancers p = 9.76x10-11) 
(Figure 5c & 5d, Table 3). In addition, JUND and JUNB 
motifs were enriched in superenhancers in both cell lines 
(in HeyA8 JUND, p = 3.00x10-3; JUNB, p = 6.60x10-3; in 
IGROV1, JUND p = 1.82x10-4; JUNB, p = 2.75x10-4). A 
recent report identified TEAD as an important PAX8 co-
regulator [17]. In our dataset a TEAD-like motif flanked 
the PAX-like motif in IGROV1 but not in HeyA8 (TEAD3 
enrichment in IGROV1 superenhancers, p = 1.76x10-10, 
in IGROV1 typical enhancers, p = 9.46x10-6; TEAD1 
enrichment in IGROV1 superenhancers, p = 3.85x10-7, in 
IGROV1 typical enhancers, p = 1.07x10-11) (Figure 5c & 
5d, Table 3). 
Figure 5: Defining the PAX8 binding motif and identifying candidate co-regulators. a. A model of the DNA binding domain 
of PAX8. Binding motifs identified by MEME-ChIP using the H3K27ac positive PAX8 binding sites in the enhancer set for HeyA8 and 
IGROV1. b. Pax5 binding motif (from Jaspar [43]) was selected as the closest binding motif to the primary PAX8 binding motif based 
on the adjusted p-value across four sets of PAX8 binding sites used for motif discovery (all (A), superenhancers (S), promoters (P), and 
enhancer (E) PAX8 peaks) for HeyA8 (orange) and IGROV1 (blue). Significantly enriched motifs within ±250 bp of the summits of PAX8 
peaks in c. HeyA8 and (d) IGROV1 cells. Other than PAX-like motifs, only motifs identified in both cell lines are shown (with the exception 
of TEAD1/3, which was unique to IGROV1). The grey line at 0 bp indicates the summit of the PAX8 peak.
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Table 4: Significantly changing genes in EOC models following PAX8 knockdown.
HeyA8 IGROV1
Gene Name Fold Change P-value Gene Name Fold Change P-value
Downregulated Genes Downregulated Genes
DCDC2 -2.8 8.82E-07 SPON1 -13.4 3.50E-10
SLC7A5 -2.6 1.09E-03 KRT24 -12.0 4.32E-12
CDH5 -2.1 1.12E-05 MMP7 -6.8 4.77E-06
FAM167A -2.1 1.25E-05 APBB1IP -3.3 2.06E-07
C8ORF13 -2.0 2.25E-05 LOC644612 -3.3 5.00E-04
H2AFY2 -2.0 1.23E-03 THY1 -3.2 1.84E-08
IL11 -2.0 2.37E-04 C1ORF85 -3.1 8.82E-09
C13ORF15 -2.0 7.73E-09 STK32B -3.0 2.16E-05
PAX8 -1.9 4.57E-06 SAMD5 -3.0 4.90E-06
SCD -1.9 6.61E-06 CYP4F11 -2.8 5.45E-06
Upregulated Genes Upregulated Genes
IL1B 2.6 3.92E-05 LOC149501 8.0 1.19E-09
LOC644350 2.6 7.50E-07 KRT18P13 8.2 2.23E-10
SCG5 2.7 1.92E-06 MGC42367 8.4 8.26E-10
STC1 2.7 2.51E-05 LOC399965 8.8 6.92E-11
HNRPLL 2.7 5.59E-11 EMP1 9.1 3.39E-11
IL8 3.3 3.18E-05 ANKRD1 10.8 4.06E-09
LPXN 3.5 3.06E-07 LOC644743 11.0 1.35E-11
IL13RA2 3.9 4.50E-14 KRT8 12.2 1.74E-11
LOC728285 4.2 8.81E-09 LOC647954 12.2 5.67E-12
TGFBI 6.2 5.51E-09 CDH17 20.4 6.37E-10
Table 5: Genes commonly changing in HeyA8 and IGROV1 models following PAX8 knockdown.
 HeyA8 IGROV1
 Gene Name Fold Change P-value Fold Change P-value
AJAP1 -1.9 3.82E-10 -1.8 2.17E-09
ANKRD1 1.6 2.02E-03 10.8 4.06E-09
C20orf75 -1.7 9.06E-05 -2.8 8.22E-05
HIST1H2BK 1.9 2.20E-05 1.8 1.33E-05
HIST2H2AA3 2.0 8.41E-07 1.7 2.24E-06
HIST2H2AA4 1.9 1.79E-06 1.6 8.88E-07
HIST2H2AC 1.6 1.35E-06 1.5 3.62E-04
PAX8 -1.9 4.57E-06 -2.3 6.51E-08
PRSS23 1.5 2.10E-04 3.9 6.86E-10
SAT1 1.8 4.47E-07 1.7 2.75E-05
SIRPA -1.7 2.56E-05 -1.7 1.48E-07
STC1 2.7 2.51E-05 1.8 2.18E-05
TGFBR2 1.8 1.46E-05 1.5 2.41E-05
VASN 1.7 4.02E-07 6.0 5.38E-11
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Identifying PAX8 target genes 
Global gene expression analysis was performed to 
identify genes that are differentially expressed following 
PAX8 knockdown in HeyA8 and IGROV1 cell lines. 
Using a fold-change cutoff of 1.2, we identified 1,055 
and 1,293 differentially expressed genes (DEGs) in 
HeyA8 and IGROV1 models respectively (FDR < 0.05; 
Supplementary Table 1, validation). Table 4 lists the DEGs 
from each cell line; Table 5 lists with the genes common 
to both cell lines. We integrated gene expression changes 
with PAX8 binding sites to map PAX8 binding sites to 
target genes, leveraging topological association domains 
(TADs) coordinates from human embryonic stem cells 
[18] to annotate DEGs. TADs are megabase-scale regions, 
largely stable across different cell types, of increased 
local interaction frequency [18]. Using these annotations, 
we divided associations with PAX8 binding sites into 3 
categories: (1) direct regulatory targets, defined as DEGs 
that have a PAX8 binding site in their promoter region; 
(2) putative regulatory targets, defined as DEGs that have 
a PAX8 binding site within the same TAD but lacking 
PAX8 binding in the promoter; and (3) indirect regulatory 
targets, defined as DEGs where there is no PAX8 binding 
site within the same TAD or the promoter. 
There were 3,062 TADs with an average length of 
852.2 Kbp (range 80 Kbp - 4.44 Mbp), of which 1,482 in 
HeyA8 and 1,413 in IGROV1 contained PAX8 binding 
sites. About two thirds of TADs (2,012) had a PAX8 peak 
in at least one of the cell lines, with 884 (29%) shared 
between HeyA8 and IGROV1 models. More than half of 
the TADs containing PAX8 binding sites - 862/1483 (58%) 
in HeyA8 and 732/1413 (52%) in IGROV1 - contained just 
one or two PAX8 binding sites (Figure 6a). We found no 
correlation between the length of the TAD and the number 
of PAX8 binding sites. About a quarter of TADs - 714 
TADs in HeyA8 and 830 in IGROV1 - contained PAX8 
regulated DEGs and most TADs harboring DEGs (566 
and 619 for HeyA8 and IGROV1 respectively) contained 
a single DEG (Figure 6b). The maximum number of DEGs 
identified within the same TAD was 9 in HeyA8 and 6 in 
IGROV1; there was no correlation between the length of 
the TAD and the number of DEGs. There were 434 and 
549 TADs containing at least one PAX8 binding site and 
one DEG in HeyA8 and IGROV1 cell models respectively 
(Figure 6c-6d). The mean distance in base pairs to the 
nearest DEG within the same TAD was 309 Kbp (sd=357 
Kbp) in HeyA8 and 235 Kbp (sd=275 Kbp) in IGROV1. 
From the 1,055 DEGs for HeyA8, we identified 16 
direct regulatory targets based on PAX8 binding in the 
promoter, and 575 putative enhancer regulatory targets 
based on the presence of a PAX8 binding site within 
the same TAD. From the 1,293 DEGs for IGROV1, we 
identified 46 direct regulatory targets and 755 as putative 
enhancer regulatory targets. The larger number of direct 
regulatory targets identified in IGROV1 compared to 
Figure 6: Identification of PAX8 regulatory targets using topological association domains (TADs). a. Distribution of the 
number of PAX8 peaks per TAD. b. Distribution of the number of differentially expressed genes (DEGs) per TAD. Venn diagrams showing 
the number of TADs with at least one PAX8 peak or at least one DEG for c. HeyA8 and d. IGROV1.
Oncotarget108325www.impactjournals.com/oncotarget
Table 6: PAX8 putative enhancer regulatory targets. 
Gene Symbol
HeyA8 IGROV1
p-value Fold change p-value Fold change
ANKRD1 2.02E-03 1.57 4.06E-09 10.79
VASN 4.02E-07 1.74 5.38E-11 6.04
IL1B 3.92E-05 2.57 1.10E-04 1.26
PAX8 4.57E-06 -1.95 6.51E-08 -2.35
CLIC3 1.19E-04 1.25 1.58E-03 2.07
HIST2H2AA3 8.41E-07 2.00 2.24E-06 1.73
AJAP1 3.82E-10 -1.94 2.17E-09 -1.77
SLC26A2 1.50E-03 -1.29 2.51E-06 -1.91
HIST1H2BK 2.20E-05 1.90 1.33E-05 1.85
GCLM 5.78E-06 -1.33 3.94E-05 -1.87
HIST2H2AA4 1.79E-06 1.86 8.88E-07 1.56
MXD4 3.62E-04 1.73 1.10E-04 1.35
ELFN2 7.37E-05 -1.50 7.67E-06 -1.72
RRAS2 6.42E-04 -1.45 5.91E-08 -1.69
CTSL2 1.65E-04 -1.41 6.56E-09 -1.61
SLC25A15 6.35E-07 -1.59 4.85E-06 -1.61
HIST2H2AC 1.35E-06 1.59 3.62E-04 1.50
ATOX1 6.52E-05 1.26 8.64E-07 1.52
CASP1 3.96E-08 1.52 5.99E-04 1.24
S100A13 7.89E-06 -1.51 2.82E-04 -1.36
EVI5L 8.13E-06 1.26 9.11E-07 1.46
CEP55 5.11E-05 -1.45 2.16E-03 -1.21
UBA7 7.76E-05 1.44 7.35E-06 1.29
CHAF1A 5.70E-05 -1.24 1.21E-04 -1.43
SKA3 9.17E-04 -1.36 7.51E-04 -1.41
SH3BGRL3 5.28E-08 1.41 3.79E-04 1.23
PTPRF 8.77E-10 1.41 1.32E-05 1.35
S100A6 5.02E-04 1.34 4.37E-05 1.41
NRP1 4.26E-06 1.36 1.09E-05 1.39
EHD2 4.79E-04 1.29 6.48E-04 1.39
XPO4 2.85E-03 -1.36 2.78E-05 -1.37
RHOC 7.17E-07 1.37 1.26E-04 1.24
KIAA1539 2.13E-07 1.29 4.36E-04 1.36
JARID2 1.27E-03 1.28 8.05E-06 1.36
CASP4 2.59E-03 1.21 3.46E-05 1.36
TROAP 1.02E-03 -1.31 2.81E-03 -1.36
DUSP28 1.25E-03 1.31 7.97E-05 1.34
SEPW1 6.62E-05 1.33 1.63E-03 1.30
FEN1 9.88E-06 -1.33 8.67E-05 -1.23
ACAA2 1.45E-03 -1.21 5.36E-05 -1.33
MPHOSPH8 7.94E-04 -1.30 4.22E-04 -1.31
POLR3K 4.38E-04 -1.27 1.83E-04 -1.31
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HeyA8 reflects the higher global enrichment of PAX8 
binding sites in promoter regions in this cell line. We 
identified SEPW1 as a direct regulatory target in both cell 
lines and 54 additional genes that are both differentially 
expressed following PAX8 knockdown and have PAX8 
binding at an enhancer in the same TAD in both cell lines 
(Table 6). 
Finally, we used both direct and putative enhancer 
regulatory targets for HeyA8 (589 DEGs) and IGROV1 
(801 DEGs) to perform pathway enrichment analysis 
using Metascape [19]. We identified 5 enriched pathways 
in common in both HeyA8 and IGROV1 cell lines: DNA 
replication, response to lipopolysaccharide (LPS), tumor 
necrosis factor alpha (TNFA) signaling via nuclear factor-
kappaB (NFKB), extracellular matrix organization and 
anatomical structure morphogenesis. The top 20 enriched 
gene sets and pathways are shown in Figure 7.
DISCUSSION
Characterizing transcription factors (TFs) 
deregulated during tumorigenesis has provided key 
insights into disease etiology, disease origins, and 
therapeutic targeting for many tumor types. By identifying 
the TFs responsible for higher-order deregulation of gene 
expression we can better understand the evolution of the 
key transcriptional networks driving tumorigenesis and 
more potently target tumor cells by inhibiting a factor 
that simultaneously deregulates tens to hundreds of proto-
oncogenes and tumor suppressor genes. Examples of 
such factors include the androgen receptor (AR), a TF 
involved in normal prostate development which becomes 
reprogrammed during prostate carcinogenesis [20]. AR 
is targeted by anti-androgenic therapies used for the 
treatment of prostate cancer and in tumors cooperates 
with HOXB13 [20], a gene that when mutated causes 
predisposition to prostate cancer [21]. Similarly, the 
estrogen receptor (ER) is targeted by tamoxifen for the 
treatment of ER positive breast cancer, and co-operates 
with the FOXA1 TF to drive breast cancer progression 
[22].
The role of TFs deregulated in epithelial ovarian 
cancer (EOC) are poorly characterized, although a 
handful of TFs and chromatin remodelers are known 
to be deregulated in a histotype-specific manner. For 
example, WT1 is a marker of serous tumors, and ARID1A 
is somatically mutated in ~50% of clear cell and ~30% 
of endometrioid tumors [23]. In this study we sought 
to understand in detail the mechanistic underlying the 
putative master regulator of EOC development, PAX8. 
PAX8 has most frequently been associated with the 
development of high-grade serous ovarian cancers 
(HGSOCs); but as this and other studies have shown, 
PAX8 is commonly expressed by other major EOC 
histotypes. Our phenotypic characterization in PAX8 
knockdown models is consistent with previous studies 
showing that PAX8 is involved in proliferation of EOC 
cells in vitro, and PAX8 knockdown impairs tumor 
formation in vivo [12-15]. 
We sought to characterize, in detail, the PAX8 
cistrome, as the binding regions for this factor have 
only been delineated for a small number of cell lines, 
and only in HGSOC [24]. To characterize the landscape 
of PAX8 binding within the context of chromatin state, 
we integrated PAX8 ChIP-seq data with maps of global 
histone activation generated by performing ChIP-seq for 
H3K27ac in the same two EOC cell lines. To link PAX8 
binding sites to target genes, we measured differential 
gene expression following PAX8 knockdown. Many 
studies assign TF ChIP-seq peaks to DEGs within a 
specified genomic window to map associations between 
DEGs and TF binding sites. However, the selection of the 
window size can often be arbitrary leading to results that 
might not be robust. Since the genome is subdivided into 
FOXM1 2.30E-06 -1.29 1.24E-04 -1.26
NUP210 2.99E-03 -1.20 9.35E-05 -1.29
POLD1 7.56E-08 -1.28 1.92E-03 -1.23
CHTF18 3.49E-04 -1.26 2.28E-03 -1.28
CDCA5 1.41E-03 -1.24 6.80E-05 -1.28
DSCC1 2.08E-05 -1.28 4.92E-05 -1.28
FRAT2 8.96E-04 -1.26 1.82E-03 -1.20
GPRIN1 1.16E-04 -1.25 3.79E-04 -1.25
ZNF259 3.22E-04 -1.24 7.71E-05 -1.25
FANCG 1.99E-03 -1.21 1.79E-04 -1.25
OIP5 1.46E-04 -1.22 2.65E-03 -1.25
M6PRBP1 1.99E-05 1.22 1.95E-03 1.20
Shown are the DEGs changing in the same direction when PAX8 is knocked down in HeyA8 and IGROV1, sorted by absolute 
fold change.
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topological association domains (TADs) that represent 
regions of high interaction frequencies, we instead 
leveraged TAD boundaries to link PAX8 binding sites 
to PAX8 target genes. In this study, we report that while 
PAX8 can regulate target gene expression via promoter 
binding, most PAX8 binding occurs outside of promoter 
regions, confirming a previous observation [24]. 
We explored non-promoter PAX8 binding sites in 
more detail using the H3K27ac ChIP-seq data and found 
that PAX8 binding was enriched at superenhancers, 
regions of dense H3K27ac signal that are commonly 
found at genes involved in differentiation, development 
and tumorigenesis [24]. A lack of enriched motifs for other 
co-factors suggests that PAX8 may function as a solo TF 
at promoters; alternatively, PAX8 may be a promiscuous 
TF at promoters, interacting with many other co-factors 
in a gene-specific manner. However, at enhancers and 
superenhancers, PAX8 binding sites preferentially co-
Figure 7: Pathway enrichment analysis. a. Top 20 pathways and gene sets enriched using 9 direct and 462 putative enhancer 
regulatory targets for PAX8 in HeyA8. b. Top 20 pathways and gene sets enriched using 46 direct and 739 putative enhancer PAX8 
regulatory targets in IGROV1. DNA replication (green), cellular responses to LPS (orange), TNFA signaling (purple) extracellular matrix 
organization (pink) and morphogenesis (light green) overlap between HeyA8 and IGROV1 top 20 enriched pathways.
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occurred within close proximity of the motifs of a select 
handful of TFs. Of particular interest are the Arnt::Ahr and 
JUND/JUNB motifs. JUND/JUNB, as well as TEAD1/
TEAD3 motifs (in the IGROV1 cell line) flank the summit 
of PAX8 ChIP-seq peaks, which may indicate co-binding 
of these two factors to adjacent DNA. The Arnt::Ahr motif 
is enriched at the summit of the PAX8 ChIP-seq peak, 
suggesting an alternative mechanism of co-regulation. 
Functional assays will be required to verify cooperation 
between PAX8 and these novel cofactors. Even so, there 
are potentially significant translational implications 
of these findings. Should an anti-PAX8 therapy be 
developed, a combination therapy targeting both PAX8 
and its preferred cofactors may confer the most potent 
effects. Even in the absence of a PAX8 inhibitor, inhibiting 
these cofactors may be sufficient to inactivate oncogenic 
PAX8 signaling and impair tumor growth. Functionally, 
these are promising co-targets. The aryl-hydrocarbon 
receptor (AHR) nuclear translocator (ARNT) heterodimer 
pathway activates a series of genes involved in xenobiotic 
metabolism (including cytochrome P450). Although this 
pathway is not well studied in EOC, in breast, prostate, 
and oral squamous carcinomas, AHR is implicated in cell 
migration, invasion and metastasis [25-27] and has been 
proposed as a novel therapeutic target. JUND/JUNB is 
part of the AP-1 TF complex, which has been implicated 
in a broad array of cancer-relevant phenotypes including 
proliferation and apoptosis. Interestingly JUNB can 
interact with BRCA1 [28], which, when mutated, confers 
a high risk of developing HGSOC.
There are limitations of this study. Since there are 
no TAD maps for EOC we used TADs defined in H1, a 
human embryonic stem cell line, as TADs are thought to 
be highly conserved across cell types [18]. However EOCs 
(particularly HGSOC) are highly genomically unstable, 
and contain many chromosomal rearrangements. Such 
rearrangements could disrupt TAD boundaries, removing 
or creating enhancer-target gene interactions. TAD maps 
and targeted or genome-wide chromosome conformation 
capture data (such as 4C or Hi-C) performed in the HeyA8 
and IGROV1 cell lines would be required to confirm 
the predicted physical interactions between enhancer-
associated PAX8 binding sites and the putative target 
genes. Another caveat is that we performed these studies 
in HeyA8 and IGROV1 cell lines because they have high 
expression of PAX8, form tumors in mice, and are models 
of non-subtype specific EOC. The results we present are 
thus generally applicable to all EOC, but may not reflect 
histotype-specific differences in the PAX8 cistrome.
The marked difference in PAX8 binding sites and 
target genes between the two cell lines may be due to the 
fact that they are likely different histotypes and, coming 
from different patients, the cells have different genetic 
and epigenetic backgrounds. PAX8 is overexpressed 
in many reproductive tract cancers and it is currently 
unclear if it has the same or different functions in these 
tumor types, and what the variation may be between 
patients. PAX8 activity is governed by the redox state of 
cells [29] and this may be contributing to the variation 
between HeyA8 and IGROV1 cell lines. However, the 
targets identified in the two different cell lines converged 
into common molecular pathways. As seen with many 
development-related oncogenes, several developmental 
pathways were enriched in the PAX8 cistrome: anatomical 
structural morphogenesis (which was common to both 
cell lines), tissue morphogenesis, positive regulation of 
programmed cell death, mesenchymal cell development, 
TAP63 signaling, Notch signaling and epithelial cell 
differentiation (which were cell line specific). In addition, 
supporting the in vitro and in vivo results, proliferation 
related pathways were identified: including DNA 
replication, G2M checkpoint, mitotic cell cycle process, 
DNA-directed DNA polymerase activity, regeneration, 
and KRAS signaling. Interestingly, 8 immune related 
pathways were found (cellular response to LPS, IKK/
NFKB signaling, TNFA signaling via NFKB, complement 
system, TLR2 signaling, phagocytosis, IL1A production, 
NLR signaling), two of which were shared (cellular 
response to LPS and TNFA signaling via NFKB) between 
both cell lines. The immune system was also found to be 
associated with PAX8 in another study [PMID: 22531031]. 
Of the common DEGs between HeyA8 and IGROV1 
knockdowns, AJAP1, SIRPA, TGFBR2, and C20orf75 
are cellular-adhesion related [30-33]. It is possible that 
PAX8 knockdown reduces the level of cellular adhesion, 
which may explain the reduced tumor burden in HeyA8 
xenograft mice. This may also explain the decreased 
proliferation in anchorage dependent growth conditions. 
To better characterize the PAX8 binding motif, we 
related the motif predicted through the ChIP-seq analyses 
to the predicted structure of the PAX8 protein in complex 
with DNA. PAX5 and PAX6 have been crystalized 
in complex with DNA [34, 35]. Due to its sequence 
similarity to PAX8, the PAX5/DNA complex was used 
as a template to generate a PAX8/DNA homology model. 
This revealed two subdomains, within the PAX8 DNA 
binding domain, that contact the major groove of DNA 
with greater specificity, joined by a linker domain with 
markedly lower DNA binding specificity. Importantly, 
the location of most critical bases in the motif could be 
predicted from the protein structure, which gives added 
weight to our predicted motif. Despite identifying the 
same motif in the two cell lines, there was a high degree 
of cell-type specificity in the genomic locations of the 
PAX8 binding sites and DEGs identified. The overlap was 
between 13%-22%, similar to the 26% of PAX8 binding 
sites in HGSOC cell lines that intersected the PAX8 
binding sites in the FTSEC cell lines [17]. The small 
overlap in DEGs and PAX8 binding sites, but similar set 
of pathways altered, suggests that PAX8 has a highly cell-
type specific regulatory network that focuses on a set of 
pathways involved in proliferation, migration/invasion and 
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differentiation. 
In conclusion, PAX8 is involved in transformed 
behavior of epithelial ovarian cancer cells in vitro, and 
suppresses tumor growth in vivo. We have established a 
global map of PAX8 direct and indirect regulatory targets. 
While it is clear that the PAX8 cistrome exhibits a high 
degree of cell-type specificity, analyses of deregulated 
pathways and co-factors converged on common molecular 
targets and partners that may represent important and 
much needed therapeutic targets for EOC.
MATERIALS AND METHODS
Analysis of TCGA data
TCGA microarray data were downloaded from The 
Cancer Genome Atlas portal and analyzed in ‘R’ using 
Bioconductor. Two-tailed paired T-Tests were performed 
to identify differences in PAX gene expression between 
HGSOCs and normal fallopian tube tissues.
Immunohistochemistry
Immunohistochemistry (IHC) for PAX8 (antibody 
product number 10336, Proteintech) was performed on 
sections of normal ovaries and on a tissue microarray 
(TMA) containing around 160 ovarian carcinoma 
biopsies from patients with known outcome. Staining 
was confirmed on whole sections from another part of 
the tumour for ~10% of the TMA biopsies. IHC staining 
intensity was used to assess PAX8 protein expression in 
each tissue (0=negative; 1=low; 2=medium; 3=high). 
Human tissues were used with the approval of the 
institutional review board at the University of Derby.
Cell culture and PAX8 knockdown
IGROV1 (luciferase labelled) and HeyA8 ovarian 
cancer cells were cultured in Dulbecco’s Modified Eagle’s 
medium (Caisson) and RPMI base media (Lonza), 
respectively. Media were supplemented with 10% fetal 
bovine serum (FBS, Seradigm). Lentiviral supernatants 
containing individual short hairpin RNAs against PAX8 
or control shRNA was generated by co-transfection of 
HEK293T vectors with 3rd generation packaging vectors 
and PAX8-shRNAs cloned into the pLKO.1 vector 
(Sigma Aldrich) (clone IDSs: NM_003466.3-772s21c1 
(shPAX8_1), NM_03346.3-1070s21c1(shPAX8_2), 
NM_003466.2-784s1c1 (shPAX8_3), NM_003466.3-
1917s21c1 (shPAX8_4)). HeyA8 and IGROV1 cells were 
infected by overnight lentiviral transduction and positive 
cells selected using 800 (HeyA8) or 200 (IGROV1) ng 
mL-1 puromycin (Sigma-Aldrich). Cell line authentication 
was performed on all cell lines using the Promega 
Powerplex 16HS Assay (performed at the University 
of Arizona Genetics Core facility). All cultures were 
confirmed to be free of Mycoplasma infections using a 
Mycoplasma specific PCR.
RT-qPCR 
RNA was harvested using the Quick-RNA MiniPrep 
kit (Zymo Research) and reverse transcribed to cDNA 
using the M-MLV reverse transcriptase (Promega) 
or the SuperScript III First-Strand Synthesis System 
(Invitrogen). Target gene expression was normalized to 
ACTB and GAPDH expression (Life Technologies), and 
relative expression calculated using the ∆∆Ct method. 
Probe information can be found in Supplementary Table 2.
In vitro phenotypic assays
Growth curves were performed by plating 1-2 
x105 cells into triplicate P60 dishes and passaging and 
counting cells at regular intervals. Population doublings 
(PDs) were calculated using the following formula 
PD = log (final cell number/initial cell number)/log2, and 
cumulative population doublings plotted. For anchorage 
independent growth assays 1-3 x103 cells were suspended 
in culture media containing 0.33% Noble Agar (Sigma 
Aldrich), plated on top of a base layer of culture media 
containing 0.6% Noble Agar. After 4 weeks colonies 
were stained by overnight incubation at 37ºC with 1% 
p-iodonitrotetrazolium violet (Sigma) dissolved in 100% 
methanol (VWR). Colonies were visualised and counted 
by phase microscopy.
In vivo tumorigenicity assays
Xenograft assays were performed under the approval 
and guidance of the University of Southern California 
Institutional Animal Care and Use Committee. 8 million 
cells were injected intra-peritoneally into 6-week old nu/
nu mice (Simonsen Laboratories). Animals were sacrificed 
after 28 days and tumors were measured by digital caliper. 
After measurement tumors were fresh frozen for tissue 
sectioning.
Microarray analyses
RNA was isolated in triplicate and gene expression 
microarray profiling performed using the Illumina 
HumanHT-12 v4 Expression BeadChips. Arrays were run 
at the University of Southern California Epigenome Core 
and University of California at Los Angeles Neuroscience 
Genomics Core, using standard protocols. Data analysis 
was performed using Partek Genomics Suite. For each 
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cell line triplicate arrays for two independent knockdown 
clones were compared to control shRNA and parental 
samples. 
Chromatin immunoprecipitation sequencing
Chromatin immunoprecipitation sequencing (ChIP-
seq) was performed based on the methods of Schmidt 
et al. [36]. Cells were fixed in 1% formaldehyde for 10 
minutes, and quenched with glycine. Cells were harvested, 
lysed in a sarkosyl-containing buffer, and sonicated using 
the Covaris E220evolution Focused-Ultrasonicator. 10 
μg of an antibody raised against PAX8 (NBP1-32440, 
Novus) or 5 μg of an antibody raised against lysine 27 
acetylated histone 3 (H3K27ac) (C15410196, Diagenode) 
was incubated with 100 μg and 4ug, respectively, of 
chromatin at 4°C overnight. Blocked magnetic Dynabeads 
(Life Technologies) were then added to the antibody-lysate 
conjugates and incubated at 4°C for 4 hours with rotation. 
Beads were then washed with RIPA buffer and treated with 
RNase and proteinase K (both Qiagen). DNA was eluted 
from the beads in Tris-EDTA buffer and cleaned up using 
the QIAquick PCR Purification kit (QIAgen). For each cell 
line two independent immunoprecipitations and one input 
sample were submitted for next-generation sequencing at 
the USC Epigenome Core Facility. 
ChIP-seq data analysis
ChIP-seq data were processed using MACS2 [37] 
with p-value cutoff of 0.001. The smaller of input or 
signal was linearly scaled to the same depth as the larger 
dataset. In order to control the irreproducible discovery 
rate in ChIP-seq analysis, we used IDR [38] version 2.0 
pipeline with a threshold of p < 0.05. After mapping to 
hg19 with BWA [39] and removing duplicates, there were 
>15 million high-quality reads for all ChIP-seq replicates. 
We used SPP [40] to calculate the cross-correlation QC 
metrics (Supplementary Tables 3 & 4) and MACS2 + 
IDR to obtain the rescue ratio and self-consistency ratio 
for each cell line. In addition, we used SPP+IDR for peak 
calling and compared with the MACS2+IDR peaks. We 
found that ~94% of the peaks called by MACS2+IDR 
pipeline where included in the SPP+IDR pipeline, which 
gives us confidence to use the MACS2+IDR peaks for 
discovery of the PAX8 cistrome.
HeyA8 and IGROV1 have 21,563 (average length = 
~2.4 Kbp) and 15,030 (average length = ~2 Kbp) H3K27ac 
enriched regions, respectively. We used HOMER [41] 
to broadly identify super enhancer regions using the 
H3K27ac ChIP-seq peaks for individual replicates. Then, 
to avoid inclusion of non-reproducible peaks in this 
analysis, we merged the MACS2+IDR H3K27ac peaks 
that overlap the super enhancer regions identified by 
HOMER, and used the MACS2+IDR/HOMER regions as 
the superenhancer regions for each cell line.
For motif discovery, we used the web application 
MEME-ChIP [42] using all PAX8 peaks for each cell 
line, individually. To associate the differentially expressed 
genes and the ChIP-seq PAX8 peaks, we used a set of 
topological association domains (TADs) for H1 embryonic 
stem cells [18].
Pathway enrichment analysis was performed 
with the web application Metascape [19], using a 
custom analysis including “Oncogenic signatures”, 
“GO Molecular Function”, “Canonical Pathways”, “GO 
Biological Processes”, Hallmark Gene Sets”, and “KEGG 
Pathway” with the default parameters.
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